Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Septic Shock
Interventions: hydrocortisone, Normal Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV-1-infection
Interventions: [89]Zr-DFO-VRC-HIVMAB060-00-AB; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis
Interventions: 13C6-Glucose; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome
Interventions: SeptiCyte (various); Diagnostic Test
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Lymphoma
Interventions: filgrastim, rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 6 more

Conditions: Cytokine Storm (Covid-19)
Interventions: Ruxolitinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more

Conditions: Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 152
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 149 more

Conditions: Candidemia
Interventions: Anidulafungin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 7 more

Conditions: Sepsis, Disseminated Intravascular Coagulation
Interventions: ART-123, placebo; Drug
Lead sponsor: Artisan Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more

Conditions: COVID-19
Interventions: Prazosin, Standard of care; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions: Pristine™ Long-Term Hemodialysis Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 6
States / cities: Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions: filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 10 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Group B Streptococcus Neonatal Sepsis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Infection, Bacteremia, Pneumonia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Late-onset Sepsis
Interventions: Ceftaroline Fosamil, Ampicillin, Aminoglycoside; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Days to 59 Days
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Pemetrexed; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sepsis, COVID-19
Interventions: Not listed
Lead sponsor: Cytovale, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Respiratory Distress, Acute Lung Injury
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness, ICUAW, Sarcopenia, Secondary Sarcopenia
Interventions: Electrical Muscle Stimulation System; Device
Lead sponsor: Health Discovery Labs; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Rochester, Minnesota • Austin, Texas

Conditions: Central Venous Catheter Exit Site Infection, Central Venous Catheter Related Bloodstream Infection
Interventions: Central venous access device (CVAD) Snuggie Securement Device; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: penclomedine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Covid19
Interventions: Selenium (as Selenious Acid), Placebo; Drug · Other
Lead sponsor: CHRISTUS Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Longview, Texas

Conditions: Severe Sepsis, Septic Shock, Bacteremia
Interventions: Not listed
Lead sponsor: University of British Columbia; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

Gene Expression Objective Definition of Early Sepsis In Children

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

Risk Factors, Costs, and Impacts of ED Boarding

The Pristine Post-Market Study

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Rapid Detection of Group B Strep- 35-37 Week Study

Pharmacodynamic Parameters of Two Different Doses of Cefepime

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

SQuISH-COVID: A Pilot Study

Lung Injury Prediction Study

MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients

A New Securement Method for External Tunneled Central Venous Access Devices (CVAD)

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock